Should Testosterone Replacement be Offered to Hypogonadal Men Treated Previously for Prostatic Carcinoma?

D. Landau; T. Tsakok; S. Aylwin; S. Hughes*


Clin Endocrinol. 2012;76(2):179-181. 

In This Article

Testosterone Replacement in Men Treated for Prostate Cancer

The Endocrine Society Clinical Practice Guideline recommends against starting testosterone replacement therapy (TRT) in hypogonadal patients with a history of prostate cancer.[8] Yet, 70 years from the seminal studies conducted by Huggins,[2] some now question our continuing adherence to their original hypotheses. The central issue is this: it is widely accepted that lowering serum testosterone may induce regression of metastatic prostate cancer, but it does not necessarily follow that an increase in serum testosterone invariably stimulates tumour growth. Indeed, review of the literature reveals a striking paucity of data to support the latter statement, prompting some to ask whether denying TRT to symptomatic hypogonadal men can be ethically justified.[9] This question has been brought sharply into focus by the increasing numbers of patients affected by both prostate cancer and late-onset hypogonadism in our ageing population.

To answer the title's clinical question, we should delve deeper into the – albeit limited – data on TRT in men previously treated for prostate cancer with curative intent. The importance of this last caveat lies in the fact that men still suspected of harbouring prostate cancer cells are broadly accepted to be unsuitable candidates for TRT.[9] By contrast, patients in long-term remission after radical surgery or radiotherapy are even more vulnerable than the average elderly men to suffer from hypogonadism, and the risk/benefit ratio of treating this has been the subject of some investigation.[10–16] On the whole, the published series, summarised in Table 1, were not prospective protocols but either open-label use in clinical settings or retrospective chart reviews.

Testosterone replacement therapy after radical prostatectomy was the focus of Kaufman and Graydon's[17] study in seven patients with hypogonadism over a maximum follow-up period of 12 years. They reported symptomatic improvement of hypogonadism, with no evidence of cancer recurrence. Agarwal and Oefelein[18] administered TRT to a similar group of 10 patients and also reported that no PSA recurrences were associated with rises in mean serum testosterone from 197 to 591 ng/dl. In a study by Khera et al.,[19] 57 men received testosterone for an average of 36 months following radical prostatectomy – no increases in PSA were seen over a mean follow-up of 13 months. Of note is the larger study by Sathyamoorthy et al.[20] in 133 postprostatectomy patients, 21 (16%) of whom had either Gleason score ≥ 8, positive margins or nodes. There were no significant PSA rises associated with increases in mean testosterone levels from 262 to 418 ng/dl over a 1 year follow-up. A prospective study of 22 patients by Nabulsi et al.[21] reported that one patient (4·5%) experienced biochemical recurrence after TRT postradical prostatectomy.

Despite the intuitive concern that residual prostate tissue is more likely to result in residual microscopic disease susceptible to androgen stimulation, some studies evaluating the use of TRT after radiotherapy and brachytherapy have also produced encouraging data. Sarosdy[22] followed 31 men receiving testosterone after brachytherapy with a median 5 year follow-up, finding no incidence of cancer recurrence or progression. Morales et al.[23] looked at five men post external beam radiotherapy and noted marked symptomatic improvement, with no biochemical recurrence for up to 27 months. Davila et al.[24] analysed PSA response after TRT in a split cohort of 20 patients after either prostatectomy or external beam radiation therapy. There were no biochemical recurrences and no differences between the two groups in PSA levels after testosterone replacement. Finally, Leibowitz et al[25] reported a retrospective study of a heterogeneously treated population of 96 patients. 60% of participants had not received definitive local therapy and consequently had both malignant and benign prostatic tissue in situ; notably, 11 men in the study group had metastatic disease in remission after ADT. After a mean treatment duration of 15 months, 41 men (43%) had PSA progression. This high rate of PSA progression can in part be explained by the relatively high proportion of patients with aggressive disease (25% had Gleason score ≥ 8). However, it is also possible that stimulation of residual benign prostatic tissue contributed to the raised PSA levels, which in most cases returned to baseline following cessation of testosterone replacement. Elevated baseline PSA before testosterone replacement was associated with a significantly increased risk of PSA progression, serving as a reminder that this therapy should be restricted to patients in overt biochemical remission.

We have summarized a small number of mostly retrospective case series evaluating the safety of initiating TRT in postprostatectomy patients with negative margins and undetectable PSA levels. Overall, 42 of 381 (11%, range 0–43%) experienced biochemical recurrence, whilst the majority benefited from symptomatic improvement in their hypogonadism without adverse effects on PSA or tumour progression. It is likely that research in this field suffers from publication bias as well as the modest quality of most studies. Nevertheless, the data presented here are largely at odds with the longstanding taboo regarding the use of androgens in men with prostate cancer and again raises the question: is it of clinical consequence if a normal serum testosterone level is achieved in a prostate cancer survivor by natural or pharmacological means? Until more studies have been published on this subject, we should take a cautious and conservative approach.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: